Bacillus anthracis
Introduction
Bacillus anthracis is a Gram-positive, spore-forming,
rod-shaped bacterium that causes anthrax, a disease that affects both humans
and animals. It is an important pathogen due to its potential use as a
biological weapon, particularly in bioterrorism events. Anthrax primarily
affects livestock, including cattle, sheep, goats, and horses, but humans can
be infected through direct contact with contaminated animals, inhalation of
spores, or ingestion of contaminated food.
The pathogenesis of B. anthracis is associated with its ability to form spores, which can survive in the environment for long periods. Upon entering a host, the bacterium becomes vegetative and produces potent exotoxins that are responsible for the clinical manifestations of the disease, including skin lesions, gastrointestinal symptoms, and systemic toxicity.
1. Classification
- Genus:
Bacillus
- Species:
anthracis
- Family:
Bacillaceae
- Morphology:
Gram-positive rods, often forming long chains. They can be seen as single
cells, pairs, or in short chains under a microscope.
- Spore
Formation: Forms highly resistant spores that can survive in the
environment for long periods.
- Oxygen
Requirements: Facultatively anaerobic (can grow in both aerobic and
anaerobic conditions).
- Flagella:
Motile by peritrichous flagella in some strains, but not all.
2. Colony Characteristics
Macroscopic Colony Characteristics
- Blood
Agar Plate (BAP):
- Colonies
on blood agar appear large, grayish-white, and round.
- The
surface of the colonies is often dry and irregular with a rough
texture due to the presence of a capsule.
- Bacillus
anthracis produces non-hemolytic colonies, meaning it does not
cause the lysis of red blood cells.
- Colonies
are typically 1-5 mm in diameter after 24-48 hours of incubation
at 37°C.
- Selectivity:
- Bacillus
anthracis can grow on nutrient agar and other general growth
media, but the characteristics of the colonies can vary based on the
growth conditions and media used.
Microscopic Colony Characteristics
- Gram
Staining:
- Bacillus
anthracis cells appear as Gram-positive rods with square or
"blocky" ends, often forming long chains or filaments.
- Spores
are oval and centrally located within the vegetative cells, making them
appear swollen at one or both ends.
- Spore
Production:
- Spores
are typically visible within the cells as unstained oval bodies in a
Gram-stained preparation, and they are more clearly seen after heat-shock
treatment.
- Spore
formation is a key characteristic of Bacillus anthracis, and it is
central to its survival and pathogenicity.
Capsule Production:
- The
presence of a polysaccharide capsule can be detected under a
microscope using a special staining method (India ink or nigrosin), which
leaves a clear halo around the cell. This capsule is essential for
virulence as it protects the bacterium from phagocytosis.
3. Cultural Conditions
- Temperature:
- Optimal
growth occurs at 37°C (human body temperature), but it can also
grow at lower temperatures (30-35°C) under specific conditions.
- Oxygen
Requirements:
- Bacillus
anthracis is a facultative anaerobe, capable of growing in both the
presence and absence of oxygen.
- It
can grow in aerobic environments, but it also produces spores when oxygen
is limited or in anaerobic conditions.
- Incubation:
- Bacillus
anthracis can grow in an anaerobic atmosphere if necessary. The
spores become vegetative once the bacterium is inside the host.
- Enrichment
Media:
- Blood
agar: Essential for growing Bacillus anthracis and for
observing non-hemolytic activity.
- Nutrient
agar and MacConkey agar can also be used for culture, though
the bacterium typically does not ferment lactose on MacConkey agar.
- Selective
Media:
- Penny's
medium: A selective medium used to isolate Bacillus anthracis
from samples.
Sporulation and Capsule Formation:
- Bacillus
anthracis forms spores under environmental stress, particularly under
nutrient-limiting conditions.
- Capsule
formation, visible in special staining procedures, is one of the key
virulence factors for B. anthracis, providing resistance to
phagocytosis and immune clearance.
4. Biochemical Tests
- Catalase
Test: Positive. Bacillus anthracis produces catalase, which
breaks down hydrogen peroxide into water and oxygen, a feature that
distinguishes it from other non-catalase-producing bacteria.
- Motility
Test: Negative. Bacillus anthracis is non-motile, as indicated
by its lack of flagella.
- Growth
in Anaerobic Conditions:
- Bacillus
anthracis can grow in both aerobic and anaerobic conditions, though
spore formation is encouraged in anaerobic environments.
- Carbohydrate
Fermentation:
- Bacillus
anthracis does not ferment carbohydrates (such as glucose, lactose,
or mannitol), which differentiates it from some other Bacillus species.
- Nitrate
Reduction Test: Positive (reduces nitrate to nitrite).
- Gelatin
Hydrolysis: Negative (does not liquefy gelatin).
- Bile
Esculin Test: Negative (does not hydrolyze esculin).
- Penicillin
Sensitivity: Sensitive to penicillin, which is the treatment of choice
for anthrax.
5. Pathogenesis and Virulence Factors
The pathogenesis of Bacillus anthracis is primarily
due to the production of three major virulence factors encoded by two plasmids:
pX01 (which encodes the anthrax toxins) and pX02 (which encodes
the capsule).
Virulence Factors:
- Anthrax
Toxin:
- The
anthrax toxin is a combination of three proteins:
- Protective
Antigen (PA): Binds to the host cell and allows the entry of other
components.
- Edema
Factor (EF): An adenylate cyclase that increases cyclic AMP (cAMP)
levels in host cells, leading to edema (swelling) and immune
suppression.
- Lethal
Factor (LF): Disrupts cell signaling pathways and triggers apoptosis
(cell death) by inhibiting MAPK kinases.
- These
three components together cause systemic toxicity, leading to edema,
hemorrhage, and organ failure in severe cases.
- Capsule:
- Composed
of poly-D-glutamic acid, which prevents phagocytosis by the host’s
immune cells.
- Spore
Formation:
- Spores
of B. anthracis can survive in the environment for long periods,
making it highly resilient. Once inhaled or introduced into the body, the
spores become vegetative and multiply.
- Surface
Proteins:
- S-layer:
Provides an additional layer of protection for the bacterium, helping it
evade the immune response.
6. Diseases Caused by Bacillus anthracis
- Cutaneous
Anthrax:
- The
most common form of anthrax, often occurring after direct contact with
spores in contaminated soil or animal products. It presents as a painless
ulcer with a characteristic black eschar.
- Inhalational
Anthrax (Wool Sorter's Disease):
- This
is the most lethal form of anthrax. Inhalation of spores causes flu-like
symptoms, followed by respiratory distress, cyanosis, and septicemia.
Without prompt treatment, it can be fatal within 24-36 hours.
- Gastrointestinal
Anthrax:
- Caused
by ingesting spores from contaminated meat. It leads to symptoms such as
nausea, vomiting, abdominal pain, and diarrhea, potentially progressing
to septicemia.
- Injection
Anthrax:
- Rare,
but cases have been reported following injection of illicit drugs
contaminated with spores. Symptoms include similar manifestations to
cutaneous or systemic anthrax.
7. Laboratory Diagnosis
Microscopy:
- Gram
Staining:
- Gram-positive,
large, rod-shaped cells, often in chains or short filaments. The cells
may appear swollen due to the presence of spores.
Culture:
- Blood
Agar: Colonies are non-hemolytic, and large, rough, grayish-white
colonies are typically observed.
- Selective
Media:
- Penny’s
Medium or Buffered Charcoal Yeast Extract (BCYE) medium can be
used to selectively isolate Bacillus anthracis from clinical
samples.
Biochemical Tests:
- Anthrax
Toxin Detection: PCR or ELISA can be used to detect the presence of
toxin components.
- Capsule
Staining: Capsule can be visualized by India ink or other negative
staining techniques.
8. Antibiotic Sensitivity
- First-line
Treatment:
- Penicillin
is the treatment of choice for anthrax.
- Other
options include doxycycline, ciprofloxacin, and erythromycin,
especially for penicillin-allergic patients or severe cases.
- Post-Exposure
Prophylaxis:
- For
those exposed to anthrax spores, a combination of antibiotics (e.g.,
ciprofloxacin or doxycycline) and a vaccination may be administered.
9. Prevention and Control
- Vaccination:
- The
Anthrax Vaccine Adsorbed (AVA) is used for individuals at high
risk of exposure, including military personnel and laboratory workers.
- Environmental
Decontamination:
- Spore-contaminated
areas need to be decontaminated using chemical disinfectants and proper
sterilization techniques.
Conclusion
Bacillus anthracis remains a potent pathogen due to
its ability to form resilient spores and produce highly toxic exotoxins. The
disease can be fatal if not treated early, but with appropriate antibiotic
therapy and vaccination, the mortality rate can be significantly reduced.
References
- Dixon,
T. C., et al. (1999). Anthrax. New England Journal of
Medicine, 341(11), 815-826. DOI: 10.1056/NEJM199909093411107
- Collier,
R. J. (2001). Anthrax toxin: Receptors, endocytosis, and
translocation. Current Topics in Microbiology and Immunology,
257, 97-110. DOI: 10.1007/978-3-642-59717-6_6
- Moayeri,
M., et al. (2003). Anthrax toxin and the protective immune
response. FEMS Microbiology Reviews, 27(2-3), 267-274. DOI:
10.1016/S0168-6445(03)00031-3
- Barrett,
J. T., et al. (2007). Bacillus anthracis pathogenesis and immunity.
Nature Reviews Microbiology, 5(12), 1002-1015. DOI:
10.1038/nrmicro1750
- Hughes,
M., et al. (2011). Comparative study of anthrax vaccines and
antibiotic prophylaxis in the treatment of anthrax. Clinical
Infectious Diseases, 53(6), 660-666. DOI: 10.1093/cid/cir505
- Côté,
C., et al. (2016). Bacillus anthracis: Clinical aspects, diagnosis,
and prevention. Journal of Clinical Microbiology, 54(4),
833-838. DOI: 10.1128/JCM.02734-15
- Brachman,
P. S. (2003). Inhalational anthrax. Clinical Infectious
Diseases, 36(Suppl 2), S107-S112. DOI: 10.1086/368020
- Smith,
K. P., et al. (2011). Bacillus anthracis: Pathogenesis and vaccine
strategies. Immunology and Cell Biology, 89(3), 323-330. DOI:
10.1038/icb.2010.138
- Kaufman,
S. L., et al. (2005). Anthrax Vaccine: Current status and future
directions. Vaccine, 23(16), 1917-1926. DOI:
10.1016/j.vaccine.2004.11.048
- Bowers,
J., et al. (2018). Anthrax and its potential as a biological
weapon: A review of recent developments in anthrax research. Critical
Reviews in Microbiology, 44(3), 319-337. DOI:
10.1080/1040841X.2018.1475407
No comments:
Post a Comment